Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose 2.6% on Friday . The company traded as high as $11.32 and last traded at $11.28, with a volume of 194,872 shares changing hands. The stock had previously closed at $10.99.

VNDA has been the subject of a number of recent research reports. Brean Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 27th. Jefferies Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Vanda Pharmaceuticals in a research report on Saturday, May 7th. Finally, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $15.92.

The stock’s market capitalization is $486.33 million. The company has a 50-day moving average of $11.08 and a 200-day moving average of $9.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. During the same period in the prior year, the company posted ($0.10) EPS. The firm had revenue of $33.30 million for the quarter, compared to analyst estimates of $32.48 million. The business’s revenue for the quarter was up 50.0% compared to the same quarter last year. On average, equities analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.83) earnings per share for the current year.

An institutional investor recently raised its position in Vanda Pharmaceuticals stock. J. Goldman & Co LP boosted its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 902,839 shares of the biopharmaceutical company’s stock after buying an additional 151,079 shares during the period. Vanda Pharmaceuticals makes up approximately 0.9% of J. Goldman & Co LP’s portfolio, making the stock its 25th largest position. J. Goldman & Co LP owned 2.11% of Vanda Pharmaceuticals worth $8,405,000 as of its most recent filing with the SEC.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.